Switch theme
Sign up to access all valuation multiples
Newron Pharmaceuticals SpA is a Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Geographically the research and development activities are performed in Italy and the United States.
1999
22
LTM Revenue $40.3M
LTM EBITDA $12.2M
$221M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Newron Pharmaceuticals has a last 12-month revenue (LTM) of $40.3M and a last 12-month EBITDA of $12.2M.
In the most recent fiscal year, Newron Pharmaceuticals achieved revenue of $61.7M and an EBITDA of $31.1M.
Newron Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Newron Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $40.3M | XXX | $61.7M | XXX | XXX | XXX |
| Gross Profit | $40.3M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | $12.2M | XXX | $31.1M | XXX | XXX | XXX |
| EBITDA Margin | 30% | XXX | 50% | XXX | XXX | XXX |
| EBIT | $8.9M | XXX | $31.4M | XXX | XXX | XXX |
| EBIT Margin | 22% | XXX | 51% | XXX | XXX | XXX |
| Net Profit | $0.6M | XXX | $19.0M | XXX | XXX | XXX |
| Net Margin | 2% | XXX | 31% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $51.3M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Newron Pharmaceuticals's stock price is CHF 7 (or $9).
Newron Pharmaceuticals has current market cap of CHF 146M (or $175M), and EV of CHF 184M (or $221M).
See Newron Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $221M | $175M | XXX | XXX | XXX | XXX | $0.06 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Newron Pharmaceuticals has market cap of $175M and EV of $221M.
Newron Pharmaceuticals's trades at 3.6x EV/Revenue multiple, and 7.1x EV/EBITDA.
Equity research analysts estimate Newron Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Newron Pharmaceuticals has a P/E ratio of 267.7x.
See valuation multiples for Newron Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $175M | XXX | $175M | XXX | XXX | XXX |
| EV (current) | $221M | XXX | $221M | XXX | XXX | XXX |
| EV/Revenue | 5.1x | XXX | 3.6x | XXX | XXX | XXX |
| EV/EBITDA | 16.9x | XXX | 7.1x | XXX | XXX | XXX |
| EV/EBIT | 23.3x | XXX | 7.0x | XXX | XXX | XXX |
| EV/Gross Profit | 5.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 267.7x | XXX | 9.2x | XXX | XXX | XXX |
| EV/FCF | 19.2x | XXX | -10.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNewron Pharmaceuticals's last 12 month revenue growth is -24%
Newron Pharmaceuticals's revenue per employee in the last FY averaged $2.8M, while opex per employee averaged $1.4M for the same period.
Newron Pharmaceuticals's rule of 40 is -155% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Newron Pharmaceuticals's rule of X is -30% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Newron Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -24% | XXX | -10% | XXX | XXX | XXX |
| EBITDA Margin | 30% | XXX | 50% | XXX | XXX | XXX |
| EBITDA Growth | -113% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -155% | XXX | 26% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -30% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $2.8M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 0% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 27% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 49% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Newron Pharmaceuticals acquired XXX companies to date.
Last acquisition by Newron Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Newron Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Newron Pharmaceuticals founded? | Newron Pharmaceuticals was founded in 1999. |
| Where is Newron Pharmaceuticals headquartered? | Newron Pharmaceuticals is headquartered in Switzerland. |
| How many employees does Newron Pharmaceuticals have? | As of today, Newron Pharmaceuticals has 22 employees. |
| Is Newron Pharmaceuticals publicy listed? | Yes, Newron Pharmaceuticals is a public company listed on SWX. |
| What is the stock symbol of Newron Pharmaceuticals? | Newron Pharmaceuticals trades under NWRN ticker. |
| When did Newron Pharmaceuticals go public? | Newron Pharmaceuticals went public in 2006. |
| Who are competitors of Newron Pharmaceuticals? | Similar companies to Newron Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Newron Pharmaceuticals? | Newron Pharmaceuticals's current market cap is $175M |
| What is the current revenue of Newron Pharmaceuticals? | Newron Pharmaceuticals's last 12 months revenue is $40.3M. |
| What is the current revenue growth of Newron Pharmaceuticals? | Newron Pharmaceuticals revenue growth (NTM/LTM) is -24%. |
| What is the current EV/Revenue multiple of Newron Pharmaceuticals? | Current revenue multiple of Newron Pharmaceuticals is 5.1x. |
| Is Newron Pharmaceuticals profitable? | Yes, Newron Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Newron Pharmaceuticals? | Newron Pharmaceuticals's last 12 months EBITDA is $12.2M. |
| What is Newron Pharmaceuticals's EBITDA margin? | Newron Pharmaceuticals's last 12 months EBITDA margin is 30%. |
| What is the current EV/EBITDA multiple of Newron Pharmaceuticals? | Current EBITDA multiple of Newron Pharmaceuticals is 16.9x. |
| What is the current FCF of Newron Pharmaceuticals? | Newron Pharmaceuticals's last 12 months FCF is $10.8M. |
| What is Newron Pharmaceuticals's FCF margin? | Newron Pharmaceuticals's last 12 months FCF margin is 27%. |
| What is the current EV/FCF multiple of Newron Pharmaceuticals? | Current FCF multiple of Newron Pharmaceuticals is 19.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
